A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer

2025-522731-34-00 Protocol D8991C00002 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 23 Jan 2026 · Status Ongoing, recruiting · 3 EU/EEA countries · 6 sites · Protocol D8991C00002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 34
Countries 3
Sites 6

Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
23 Jan 2026 → ongoing
Decision date (initial)
2026-01-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

VersionLevelCodeTermSystem organ class
20.0 PT 10033128 Ovarian cancer 100000004864
24.1 LLT 10086155 Primary peritoneal carcinosarcoma 100000004848
20.0 PT 10016180 Fallopian tube cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Locations

3 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Ireland Ongoing, recruiting 13 1
Portugal Ongoing, recruiting 4 1
Spain Ongoing, recruiting 17 4
Rest of world 0

Investigational sites

Ireland

1 site · Ongoing, recruiting
Mater Misericordiae University Hospital
3901: START Dublin, Eccles Street, D07 R2WY, Dublin 7

Portugal

1 site · Ongoing, recruiting
Start Research Portugal Unipessoal Lda.
351217805000, Rua Castilho 39 8º E, 1250-068, Lisbon

Spain

4 sites · Ongoing, recruiting
Hospital Universitario Hm Sanchinarro
7001: CIOCC Phase I Unit, Calle Ona 10, 28050, Madrid
Fundacion Rioja Salud
7003: Early Phase Clinical Trials, Calle Piqueras 98, 26006, Logrono
Hospital Universitario Fundacion Jimenez Diaz
7004: Phase I Clinical Trials Unit, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Hm Nou Delfos
7002: CIOCC Early Phase, Avinguda De Vallcarca 151, 08023, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Ireland 2026-02-05 2026-02-09
Portugal 2026-02-17 2026-03-02
Spain 2026-01-23 2026-01-26

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-12 Spain Acceptable
2026-01-14
2026-01-15
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-01-22 Spain Acceptable
2026-01-14
2026-01-22
3 SUBSTANTIAL MODIFICATION SM-1 2026-01-23 Acceptable 2026-02-10
4 NON SUBSTANTIAL MODIFICATION NSM-2 2026-04-27 Spain Acceptable 2026-04-27